On 5 August 2013, orphan designation (EU/3/13/1181) was granted by the European Commission to Dr Falk Pharma GmbH, Germany, for budesonide for the treatment of eosinophilic oesophagitis.
Budesonide has been authorised in the EU as Jorveza since 8 January 2018.
|Disease / condition||
Treatment of eosinophilic oesophagitis
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.